Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides

Ann Hessell, Sean McBurney, Shilpi Pandey, William Sutton, Lily Liu, Liuzhe Li, Maxim Totrov, Susan Zolla-Pazner, Nancy Haigwood, Miroslaw K. Gorny

    Research output: Contribution to journalArticle

    7 Citations (Scopus)

    Abstract

    RV144 vaccinees with low HIV-1 Envelope-specific IgA antibodies (Abs) also had Abs directed to the hypervariable region 3 (V3) that inversely correlated with infection risk. Thus, anti-V3 HIV-1 Abs may contribute to protection from HIV-1 infection. The V3 region contains two dominant clusters of epitopes; one is preferentially recognized by mAbs encoded by VH5-51 and VL lambda genes, while the second one is recognized by mAbs encoded by other VH genes. We designed a study in rhesus macaques to induce anti-V3 Abs specific to each of these two dominant clusters of V3 epitopes to test whether the usage of the VH5-51 gene results in different characteristics of antibodies. The two C4-V3 immunogens used for immunization were each comprised of a fusion of the C4 peptide containing the T cell epitope and a V3 mimotope peptide mimicking the V3 epitope. The C4-447 peptide was designed to target B cells with several VH1-VH4 genes, the C4-VH5-51 peptide was designed to specifically target B cells with the VH5-51 gene. Six animals in two groups were immunized five times with these two immunogens, and screening of 10 sequential plasma samples post immunization demonstrated that C4-447 induced higher titers of plasma anti-V3 Abs and significantly more potent neutralizing activities against tier 1 and some tier 2 pseudoviruses than C4-VH5-51. Levels of anti-V3 Abs in buccal secretions were significantly higher in sequential samples derived from C4-447- than from C4-VH5-51-immunized animals. The titers of anti-V3 Abs in plasma strongly correlated with their levels in mucosal secretions. The results show that high titers of vaccine-induced anti-V3 Abs in plasma determine the potency and breadth of neutralization, as well as the rate of transduction of Abs to mucosal tissues, where they can play a role in preventing HIV-1 infection.

    Original languageEnglish (US)
    Pages (from-to)2713-2721
    Number of pages9
    JournalVaccine
    Volume34
    Issue number24
    DOIs
    StatePublished - May 23 2016

    Fingerprint

    Macaca mulatta
    Neutralizing Antibodies
    neutralizing antibodies
    Anti-Idiotypic Antibodies
    peptides
    HIV-1
    Peptides
    antibodies
    Epitopes
    Antibodies
    Genes
    Human immunodeficiency virus 1
    epitopes
    HIV Infections
    Immunization
    B-Lymphocytes
    Peptide T
    HIV Antibodies
    T-Lymphocyte Epitopes
    Cheek

    Keywords

    • HIV vaccine
    • HIV-1
    • HIV-1 neutralizing antibodies
    • Non-human primates immunization
    • Rhesus macaque immunoglobulin genes
    • V3 immunogens

    ASJC Scopus subject areas

    • Immunology and Microbiology(all)
    • Infectious Diseases
    • Public Health, Environmental and Occupational Health
    • veterinary(all)
    • Molecular Medicine

    Cite this

    Hessell, A., McBurney, S., Pandey, S., Sutton, W., Liu, L., Li, L., ... Gorny, M. K. (2016). Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides. Vaccine, 34(24), 2713-2721. https://doi.org/10.1016/j.vaccine.2016.04.027

    Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides. / Hessell, Ann; McBurney, Sean; Pandey, Shilpi; Sutton, William; Liu, Lily; Li, Liuzhe; Totrov, Maxim; Zolla-Pazner, Susan; Haigwood, Nancy; Gorny, Miroslaw K.

    In: Vaccine, Vol. 34, No. 24, 23.05.2016, p. 2713-2721.

    Research output: Contribution to journalArticle

    Hessell, A, McBurney, S, Pandey, S, Sutton, W, Liu, L, Li, L, Totrov, M, Zolla-Pazner, S, Haigwood, N & Gorny, MK 2016, 'Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides', Vaccine, vol. 34, no. 24, pp. 2713-2721. https://doi.org/10.1016/j.vaccine.2016.04.027
    Hessell, Ann ; McBurney, Sean ; Pandey, Shilpi ; Sutton, William ; Liu, Lily ; Li, Liuzhe ; Totrov, Maxim ; Zolla-Pazner, Susan ; Haigwood, Nancy ; Gorny, Miroslaw K. / Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides. In: Vaccine. 2016 ; Vol. 34, No. 24. pp. 2713-2721.
    @article{035e83df44e24531b9ebbccefbca2770,
    title = "Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides",
    abstract = "RV144 vaccinees with low HIV-1 Envelope-specific IgA antibodies (Abs) also had Abs directed to the hypervariable region 3 (V3) that inversely correlated with infection risk. Thus, anti-V3 HIV-1 Abs may contribute to protection from HIV-1 infection. The V3 region contains two dominant clusters of epitopes; one is preferentially recognized by mAbs encoded by VH5-51 and VL lambda genes, while the second one is recognized by mAbs encoded by other VH genes. We designed a study in rhesus macaques to induce anti-V3 Abs specific to each of these two dominant clusters of V3 epitopes to test whether the usage of the VH5-51 gene results in different characteristics of antibodies. The two C4-V3 immunogens used for immunization were each comprised of a fusion of the C4 peptide containing the T cell epitope and a V3 mimotope peptide mimicking the V3 epitope. The C4-447 peptide was designed to target B cells with several VH1-VH4 genes, the C4-VH5-51 peptide was designed to specifically target B cells with the VH5-51 gene. Six animals in two groups were immunized five times with these two immunogens, and screening of 10 sequential plasma samples post immunization demonstrated that C4-447 induced higher titers of plasma anti-V3 Abs and significantly more potent neutralizing activities against tier 1 and some tier 2 pseudoviruses than C4-VH5-51. Levels of anti-V3 Abs in buccal secretions were significantly higher in sequential samples derived from C4-447- than from C4-VH5-51-immunized animals. The titers of anti-V3 Abs in plasma strongly correlated with their levels in mucosal secretions. The results show that high titers of vaccine-induced anti-V3 Abs in plasma determine the potency and breadth of neutralization, as well as the rate of transduction of Abs to mucosal tissues, where they can play a role in preventing HIV-1 infection.",
    keywords = "HIV vaccine, HIV-1, HIV-1 neutralizing antibodies, Non-human primates immunization, Rhesus macaque immunoglobulin genes, V3 immunogens",
    author = "Ann Hessell and Sean McBurney and Shilpi Pandey and William Sutton and Lily Liu and Liuzhe Li and Maxim Totrov and Susan Zolla-Pazner and Nancy Haigwood and Gorny, {Miroslaw K.}",
    year = "2016",
    month = "5",
    day = "23",
    doi = "10.1016/j.vaccine.2016.04.027",
    language = "English (US)",
    volume = "34",
    pages = "2713--2721",
    journal = "Vaccine",
    issn = "0264-410X",
    publisher = "Elsevier BV",
    number = "24",

    }

    TY - JOUR

    T1 - Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides

    AU - Hessell, Ann

    AU - McBurney, Sean

    AU - Pandey, Shilpi

    AU - Sutton, William

    AU - Liu, Lily

    AU - Li, Liuzhe

    AU - Totrov, Maxim

    AU - Zolla-Pazner, Susan

    AU - Haigwood, Nancy

    AU - Gorny, Miroslaw K.

    PY - 2016/5/23

    Y1 - 2016/5/23

    N2 - RV144 vaccinees with low HIV-1 Envelope-specific IgA antibodies (Abs) also had Abs directed to the hypervariable region 3 (V3) that inversely correlated with infection risk. Thus, anti-V3 HIV-1 Abs may contribute to protection from HIV-1 infection. The V3 region contains two dominant clusters of epitopes; one is preferentially recognized by mAbs encoded by VH5-51 and VL lambda genes, while the second one is recognized by mAbs encoded by other VH genes. We designed a study in rhesus macaques to induce anti-V3 Abs specific to each of these two dominant clusters of V3 epitopes to test whether the usage of the VH5-51 gene results in different characteristics of antibodies. The two C4-V3 immunogens used for immunization were each comprised of a fusion of the C4 peptide containing the T cell epitope and a V3 mimotope peptide mimicking the V3 epitope. The C4-447 peptide was designed to target B cells with several VH1-VH4 genes, the C4-VH5-51 peptide was designed to specifically target B cells with the VH5-51 gene. Six animals in two groups were immunized five times with these two immunogens, and screening of 10 sequential plasma samples post immunization demonstrated that C4-447 induced higher titers of plasma anti-V3 Abs and significantly more potent neutralizing activities against tier 1 and some tier 2 pseudoviruses than C4-VH5-51. Levels of anti-V3 Abs in buccal secretions were significantly higher in sequential samples derived from C4-447- than from C4-VH5-51-immunized animals. The titers of anti-V3 Abs in plasma strongly correlated with their levels in mucosal secretions. The results show that high titers of vaccine-induced anti-V3 Abs in plasma determine the potency and breadth of neutralization, as well as the rate of transduction of Abs to mucosal tissues, where they can play a role in preventing HIV-1 infection.

    AB - RV144 vaccinees with low HIV-1 Envelope-specific IgA antibodies (Abs) also had Abs directed to the hypervariable region 3 (V3) that inversely correlated with infection risk. Thus, anti-V3 HIV-1 Abs may contribute to protection from HIV-1 infection. The V3 region contains two dominant clusters of epitopes; one is preferentially recognized by mAbs encoded by VH5-51 and VL lambda genes, while the second one is recognized by mAbs encoded by other VH genes. We designed a study in rhesus macaques to induce anti-V3 Abs specific to each of these two dominant clusters of V3 epitopes to test whether the usage of the VH5-51 gene results in different characteristics of antibodies. The two C4-V3 immunogens used for immunization were each comprised of a fusion of the C4 peptide containing the T cell epitope and a V3 mimotope peptide mimicking the V3 epitope. The C4-447 peptide was designed to target B cells with several VH1-VH4 genes, the C4-VH5-51 peptide was designed to specifically target B cells with the VH5-51 gene. Six animals in two groups were immunized five times with these two immunogens, and screening of 10 sequential plasma samples post immunization demonstrated that C4-447 induced higher titers of plasma anti-V3 Abs and significantly more potent neutralizing activities against tier 1 and some tier 2 pseudoviruses than C4-VH5-51. Levels of anti-V3 Abs in buccal secretions were significantly higher in sequential samples derived from C4-447- than from C4-VH5-51-immunized animals. The titers of anti-V3 Abs in plasma strongly correlated with their levels in mucosal secretions. The results show that high titers of vaccine-induced anti-V3 Abs in plasma determine the potency and breadth of neutralization, as well as the rate of transduction of Abs to mucosal tissues, where they can play a role in preventing HIV-1 infection.

    KW - HIV vaccine

    KW - HIV-1

    KW - HIV-1 neutralizing antibodies

    KW - Non-human primates immunization

    KW - Rhesus macaque immunoglobulin genes

    KW - V3 immunogens

    UR - http://www.scopus.com/inward/record.url?scp=84963984231&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84963984231&partnerID=8YFLogxK

    U2 - 10.1016/j.vaccine.2016.04.027

    DO - 10.1016/j.vaccine.2016.04.027

    M3 - Article

    C2 - 27102818

    AN - SCOPUS:84963984231

    VL - 34

    SP - 2713

    EP - 2721

    JO - Vaccine

    JF - Vaccine

    SN - 0264-410X

    IS - 24

    ER -